AWM
TEVA icon

Abound Wealth Management’s Teva Pharmaceuticals TEVA Stock Holding History

Abound Wealth Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-10
Closed -$81 – 781
2022
Q3 		$81 Buy
+10
New +$88 ﹤0.01% 724

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Abound Wealth Management's TEVA Position: Q4 2022 in Review

Abound Wealth Management sold out of Teva Pharmaceuticals (TEVA) in Q4 2022, closing a stake of 10 shares — an estimated $81 sold.

Abound Wealth Management first reported a position in TEVA in Q3 2022 and held it in 1 quarter. The position peaked at $81 in Q3 2022. 422 funds tracked by Wall St. Rank hold TEVA as of Q4 2022.

  • Abound Wealth Management reported no remaining Teva Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Abound Wealth Management sold 10 Teva Pharmaceuticals shares in Q4 2022, an estimated $81.
  • Abound Wealth Management first reported a position in Teva Pharmaceuticals in Q3 2022 and held it in 1 quarter.
  • Abound Wealth Management's Teva Pharmaceuticals position peaked at $81 in Q3 2022.
  • 422 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2022.

Based on Abound Wealth Management's 13F filing for Q4 2022, filed 7 Aug 2024.